News & Updates

Obstructive sleep apnoea (OSA) contributes to an increased risk of cardiovascular disease (CVD) events for patients with cancer, and this risk increase persists regardless of obesity status and is more pronounced in women, according to a retrospective study.

New drug applications approved by US FDA as of 1-15 August 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

New drug applications approved by US FDA as of 16-31 July 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Ribociclib combined with letrozole or fulvestrant demonstrates robust progression-free (PFS) and overall survival (OS), with modest objective response rates in heavily pretreated patients with advanced breast cancer, according to a real-world study.

Antibody-drug conjugates (ADCs) are an important therapeutic option in advanced non-small cell lung cancer (NSCLC), but the right patient selection remains a major challenge. Professor David P. Carbone, Director, Thoracic Oncology Center, Ohio State University Medical Center, Ohio, US, discussed the evolving role of biomarkers in guiding therapy with ADC. 

Antibody-drug conjugates (ADCs) are revolutionising the treatment of cancer by combining the specificity of targeted therapy with the potency of cytotoxic chemotherapy, said Dr David Lee, a consultant clinical oncologist.